FDA Grants Prime Medicine (PRME) PM359 RMAT Status for CGD Treatment

Prime Medicine (PRME) announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational drug, PM359. The designation is for treating chronic granulomatous disease (CGD) and aims to expedite the development and review processes for serious conditions. The RMAT status was based on promising clinical data from an ongoing Phase 1/2 study of PM359. This ex vivo gene editing therapy is designed to correct the underlying genetic mutation responsible for CGD, a rare and life-threatening genetic disorder that severely impairs the immune system. The RMAT designation provides benefits such as priority review, rolling review, and potential for accelerated approval pathways, which could significantly shorten the time to market if successful.